A sample of the COVID-19 inactivated vaccine is seen at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 10, 2020. (Xinhua/Zhang Yuwei)

The construction of the workshop was completed in April with the support of the Beijing municipal government, the CNBG said.

State authorities organized the biosafety inspection in July and concluded that the workshop complies with national standards and could be used for large-scale production of COVID-19 vaccines, the company said.

With another workshop built in Wuhan, central China's Hubei Province, in July, CNBG said it will be able to produce 220 million doses of inactivated COVID-19 vaccines a year. ■